目的 前瞻性观察辛伐他汀对维持性血液透析患者血清Prohepcidin浓度的影响。方法 将26例维持性血透(MHD)患者分为实验组(13例)和对照组(13例)，测定基线血清Prohepcidin，血浆IL-6，以及血清CRP、铁蛋白、血红蛋白、白蛋白、胆固醇、甘油三酯、低密度脂蛋白和高密度脂蛋白浓度。实验组每晚口服辛伐他汀20mg共8周，对照组不使用辛伐他汀类或其它调脂药物。观察两组实验前后上述指标变化。结果 26例MHD患者实验前血清Prohepcidin浓度为(173.6±52.7)ng/mL。实验组实验前血清Prohepcidin浓度为(156.7±51.9)ng/mL， 8周后为(180.5±33.7)ng/mL，与基线相比无显著性差异，P =0.127。对照组实验前血清Prohepcidin浓度为(190.6±49.6)ng/mL, 8周后为(193.5±36.0)ng/mL，与基线相比无显著性差异，P =0.728。实验组8周后血清胆固醇和甘油三酯浓度分别降低18.6%(P =0.004)和55.1%(P=0.007)；实验及对照组实验前后血浆IL-6，血清CRP、铁蛋白、血红蛋白、白蛋白、低密度脂蛋白和高密度脂蛋白浓度无显著变化。结论 本实验初步显示，每晚口服辛伐他汀20mg 8周未能对MHD患者血清Prohepcidin浓度产生显著影响。

Objective To prospectively study the leverage of simvastatin on serum prohepcidin in maintenance hemodialysis (MHD) patients. Methods We assigned 26 MHD patients equally into experiment group and control group. Patients in the experiment group took 20mg simvastatin orally per night for 8 weeks, and those in the control group treated without statins and any other lipid modulating drugs. Before and after experiment, serum prohepcidin, plasma IL-6, and serum C-reactive protein (CRP), ferritin, hemoglobin, albumin, cholesterol, triglycerides, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were determined. Results Of the 26 MHD patients before the experiment, serum prohepcidin was 173.6±52.7ng/ml. In the experiment group, serum prohepcidin was 156.7±51.9ng/ml before the treatment, and was 180.5±33.7ng/ml after the treatment for 8 weeks (P=0.127). In the control group, serum prohepcidin was 190.6±49.6ng/mL at the beginning, and was 193.5±36.0ng/ml after 8 weeks (P=0.728). In the experiment group after simvastatin treatment for 8 weeks, serum cholesterol and triglycerides decreased by 18.6% (P=0.004) and 55.1% (P= 0.007), respectively. In the 2 groups, plasma IL-6 and serum CRP, ferritin, hemoglobin, albumin, LDL and HDL remained unchanged. Conclusion Our preliminary study demonstrated that simvastatin 20mg per day did not change serum prohepcidin significantly in MHD patients.